The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: David Joshua Saxon - Needham & Company, LLC, Research Division - Analyst
: Well, thanks so much, Steve and Lindon. That was a super helpful overview. I guess to start, I do want to touch on COVID. I think in your prepared
remarks, you called out $50 million you recognized last year. I think on the fourth quarter, fiscal fourth quarter call, cases were continuing to increase
and you do benefit from testing. So I mean, is it fair to expect a sequential increase in the COVID-driven revenue you saw in the fiscal fourth?
Question: David Joshua Saxon - Needham & Company, LLC, Research Division - Analyst
: Okay. That's fair. And then outside of C&I, what other headwinds and tailwinds are you seeing from COVID?
Question: David Joshua Saxon - Needham & Company, LLC, Research Division - Analyst
: Okay. Got it. And since we're running kind of short on time, I do want to skip ahead to the commercial model. You did talk about a change you're
making at your recent Investor Day. So can you just give us a reminder of an overview of what that looks like and kind of how long you expect that
transition to take?
Question: David Joshua Saxon - Needham & Company, LLC, Research Division - Analyst
: Okay. And then maybe a higher-level question on your fiscal '24 targets. I mean can you just talk about the level of visibility you have in each of
the 3 categories? I did imagine it's pretty high for SRS and cryo stores in the products category. So that's one. And then, number two, does the
commercial model kind of change how much visibility you can have?
Question: David Joshua Saxon - Needham & Company, LLC, Research Division - Analyst
: Okay. Great. And then there were a few questions submitted, so I want to get to these in the last minute. One is on just what areas of the life sciences
market you're looking to for M&A. And then, I mean, I'm guessing you're going to focus mostly on M&A, but there was a question about buybacks
as well.
Question: David Joshua Saxon - Needham & Company, LLC, Research Division - Analyst
: Okay. Well, with that, we're out of time. But thanks to both of you for joining, and I hope you have a productive schedule of investor meetings.
Thanks so much.
|
